Neurizon Therapeutics Limited (ASX:NUZ) has applied for quotation of 1,489,520 ordinary fully paid shares on ASX following the conversion of performance rights (NUZAG) into ordinary shares, with an issue date of 9 November 2026, according to an Appendix 2A filing lodged on the same date.

Key Points

  • 1,489,520 ordinary fully paid shares are to be quoted on ASX, issued on 9 November 2026 via conversion of performance rights.
  • Shares were issued for nil cash consideration on the vesting and exercise of performance rights, with an estimated value of $0.064000 per security.
  • Key management personnel Daniel O'Connell converted 495,020 performance rights into ordinary shares.
  • 50% of the shares issued are subject to a trading restriction until 30 June 2027, or until the end of any relevant period under the company's Trading Policy.
  • Following quotation, Neurizon Therapeutics will have 854,906,589 ordinary fully paid shares on issue.

Performance Rights Conversion Details

The 1,489,520 shares were issued as a result of the conversion of NUZAG performance rights into NUZ ordinary fully paid shares. The last date the convertible securities were converted was 9 November 2026. The filing states the securities were issued under an employee incentive scheme, and the newly quoted shares will rank equally in all respects from their issue date with the existing issued securities in the same class. No cash consideration was paid for the shares, with the filing confirming they were issued for nil consideration on the vesting and exercise of the performance rights.

Key Management Personnel Participation

According to the filing, key management personnel Daniel O'Connell converted 495,020 performance rights into ordinary shares, with those securities registered in his name. The filing identifies O'Connell as a key management person or associate involved in the conversion. The shares were issued on 9 November 2026 and are included within the total 1,489,520 securities subject to the quotation application. The filing confirms the underlying securities are intended to be, but are not yet, quoted by ASX at the time of lodgement.

Issued Capital Following Quotation

Following the quotation of the new shares, Neurizon Therapeutics will have a total of 854,906,589 ordinary fully paid shares on issue. The company's unquoted securities will include options across four classes: 384,000 options expiring 5 February 2028 at $0.26, 9,539,210 options expiring 30 June 2032 at $0.20, 2,044,025 options expiring 31 August 2033 at $0.16, and 5,947,668 options expiring 31 August 2034 at $0.0594. A further 14,756,340 NUZAG performance rights remain on issue as unquoted securities.